BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric protein. It became one of the most-requested research peptides in the wellness and longevity market on the strength of preclinical data showing accelerated tendon, ligament, and gut tissue repair. Most of that work sits in rodent or in-vitro studies rather than in human trials.
The regulatory picture shifted decisively on July 23, 2026. The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention to recommend adding BPC-157 to the Section 503A bulks list, overriding the June 29-30 FDA career-staff briefing documents that recommended against it. The vote is advisory; formal rulemaking would take approximately 6-18 months before compounding pharmacies could legally prepare BPC-157 under the 503A framework. Prior to the PCAC vote, BPC-157 sat in Category 2 (insufficient information to evaluate) and was the subject of DOJ action, state medical-board enforcement against clinics, and UK MHRA notices.
The clinical evidence base remains thin. A 2026 STAT and Undark investigation sharpened the point: nearly all of the roughly 200 BPC-157 studies on PubMed list Croatian researcher Predrag Sikiric or a close colleague as an author, the work carries undisclosed patent and commercial conflicts, and only three human studies have been published. Stories here cover new preclinical work, regulatory action, and any movement toward registered human trials. See [[pcac]] and [[peptide-compounding]] for adjacent threads.
AJSM published a comprehensive review of injectable peptide therapy for orthopedic and sports medicine, surveying BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. The authors conclude that while preclinical evidence supports tendon and muscle repair benefits, human trials are minimal — the most-cited BPC-157 human data is a single 12-patient case series with significant methodological flaws. TB-500 and BPC-157 remain WADA-banned. The piece directly addresses surgeons being asked about peptides by patients in the wake of FDA Category 2 changes.
The American Orthopaedic Society for Sports Medicine published an April 2026 update revisiting the evidence base for peptide therapy in sports medicine. The piece reflects increasing surgeon-side concerns about patients self-administering peptides for recovery from injuries and surgeries, with growing pressure from clinics offering BPC-157 and TB-500 injections. AOSSM's stance remains that current evidence is insufficient to recommend therapeutic peptide use — but the educational push acknowledges the rising clinical reality post-FDA reclassification.
Yahoo published an April 23 consumer-facing explainer titled "Wait, So Are Peptides Legal Now?" — the most widely-circulated translation of last week's FDA Category 2 removal for a mainstream audience. The piece walks through which 12 peptides were removed from the restricted list, what the July 23-24 PCAC meeting will actually decide, the distinction between reclassification and FDA approval, and the practical implications for compounding pharmacies and patients. The article marks the peptide-regulation story's transition into general consumer awareness.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
Scientific American published a comprehensive April 18 feature examining the self-injection wellness peptide movement, focusing on BPC-157, TB-500, GHK-Cu, KPV, and ipamorelin. The piece notes that only three small pilot studies have looked at BPC-157 in humans, that most evidence is from rodent models, and that consumers are ordering the compounds from overseas — usually from China — while the FDA prepares to review the category at its July advisory panel.
PharmaTher Holdings filed a U.S. provisional patent on April 13 for stabilized peptide compositions delivered via its PharmaPatch microneedle platform, covering formulations for BPC-157, GHK-Cu, TB-500, KPV, and multi-peptide combinations. The April 16 announcement positions PharmaTher to capture needle-free delivery share if the FDA's July PCAC meeting moves peptides back to Category 1. Three of the four compounds are on the July agenda.
STAT News analysis of the composition of the July 23-24 Pharmacy Compounding Advisory Committee suggests panelists are likely to vote in favor of broader peptide access. The panel will review BPC-157 (ulcerative colitis), KPV (wound healing), TB-500, MOTS-c, emideltide, semax, and epitalon — largely aligning with RFK Jr.'s February 2026 pledge to move 14 restricted peptides back to Category 1.
The FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23-24 to evaluate whether seven or more peptides — including BPC-157, TB-500, and other popular wellness peptides — should be added to the list of substances eligible for pharmacy compounding. The announcement follows HHS Secretary RFK Jr.'s February pledge to reclassify 14 restricted peptides.
Australia's Therapeutic Goods Administration warned of rising imports of unapproved peptide products promoted on social media, citing risks including severe allergic reactions, systemic inflammatory response, infection, and organ damage. Named products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 — often supplied as injectables.
Peter Attia devoted a full AMA episode to peptides, building a framework for evaluating any compound based on mechanism, evidence quality, and safety. The episode examines BPC-157, SS-31, melanotan-II, and CJC-1295, addresses grey-market risks, and maps which areas of medicine stand to benefit most.
A federal grand jury indicted Utah osteopathic physician Justin Bradley Watkins for obtaining non-FDA-approved peptides including tirzepatide, semaglutide, BPC-157, and retatrutide from a Chinese supplier, affixing fake labels, and selling them to over 200 patients without disclosing their unapproved status.
NBC News published a major investigation finding that peptides are advertised online for uses far beyond the science — wrinkle reduction, muscle growth, sleep, and libido — with U.S. peptide searches hitting 10.1 million in January 2026. Experts warned that increased accessibility is outpacing safety and efficacy evidence.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
Health Canada warned Canadians against injecting unauthorized peptides purchased online, citing risks of organ damage and infection from products misleadingly labeled 'For Research Use Only.'
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.
Researchers from UNSW examine the booming trend of injectable peptides marketed for skin repair and anti-aging. They highlight the lack of human clinical evidence and note three people were fined for peptide injections that hospitalized two women at an anti-aging festival.
In-depth feature on peptide mania in wellness culture. HHS Secretary RFK Jr. wants to make unapproved wellness peptides more available to the public. The piece distinguishes FDA-regulated peptides from the largely untested 'wellness' peptides embraced by those mistrustful of mainstream medicine.